Clinical trials: Zoledronic acid
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
Traumatic Brain Injury, Spinal Cord Injuries
Continuous Passive Motion Versus Heterotopic Ossification
The investigators hypothesize that Heterotopic Ossification (HO) formation can be suppressed if the application of a Continuous Passive Motion (CPM) device can be performed for a substantial amount of time.
- Conditions
- Traumatic Brain Injury, Spinal Cord Injuries, Stroke
- Trial name
- CPMversusHO (NCT05906056)
- Testing
- Continuous Passive Motion (CPM), Conventional physiotherapy (PT), Zoledronic Acid Injection
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- University of Ioannina
Non-small Cell Lung Cancer, Bone Metastases
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone…
- Trial name
- BLEST (NCT00765687)
- Testing
- bisphosphates
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Lung Metastases, Tumor Necrosis
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors.
- Trial name
- NCT03932071
- Testing
- Zoledronic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Primary Osteoarthritis
Effect of Zoledronic Acid in Primary Knee Osteoarthritis
We try to find out the effect of zoledronic acid over pain of primary knee osteoarthritis and also functional status in a period of 6 months.
- Trial name
- NCT06051344
- Testing
- Zoledronic acid
- Where
- Bangladesh
- Volunteers
- 92 people
- Sponsor
- Toufiqe-E-Ealahi
Osteoporosis, Postmenopausal
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
- Trial name
- EURODEC (NCT05575167)
- Testing
- Zoledronate or Alendronate
- Where
- 9 sites in France, Greece and 1 more
- Volunteers
- 122 people
- Sponsor
- 424 General Military Hospital
Breast Cancer With Bone Metastasis
The Role of Bisphosphonate and Simvastatin Combination on Therapeutic Response in Breast Cancer With Bone Metastasis Via Dicckopf-1 Pathway
This randomised, double-blind, placebo-controlled pilot trial evaluated the therapeutic response of zoledronic acid combined with simvastatin in women with breast cancer and confirmed bone metastases.
- Trial name
- NCT07823751
- Testing
- Simvastatin, Zoledronic Acid (Zometa)
- Where
- Indonesia
- Volunteers
- 35 people
- Sponsor
- Universitas Indonesia
Prostate Cancer
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2)…
- Trial name
- NCT00193856
- Testing
- Leuprorelin Acetate, Zoledronic Acid, Conventional external beam therapy
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 1,071 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Osteoporosis
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.
- Trial name
- NCT00361595
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Osteoporosis
Zometa Study in Pediatric Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers \& 74 % of childhood leukemia.
- Trial name
- NCT01656512
- Testing
- zolendronic acid, calcium & vitamin D
- Where
- Egypt
- Volunteers
- 95 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Breast Cancer, Castration-resistant Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA…
- Trial name
- NCT04549207
- Testing
- Bone modifying agent
- Where
- 5 sites in Canada
- Volunteers
- 240 people
- Sponsor
- Ottawa Hospital Research Institute
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Hormone-Refractory Prostate Cancer
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy.
- Trial name
- NCT00636740
- Testing
- Zoledronic Acid 20mg Tablets, Zoledronic Acid
- Where
- 13 sites in United States, Estonia and 1 more
- Volunteers
- 30 people
- Sponsor
- Merrion Pharmaceuticals, LLC
Osteoporosis, Multiple Sclerosis
Zoledronic Acid in MS-patients With Osteoporosis
This study is designed to evaluate the efficacy and safety of zoledronic acid 5 mg intravenous (i.v.) relative to placebo in Multiple Sclerosis (MS) patients with osteoporosis and to support the optimal use of zoledronic acid for…
- Trial name
- EXALT (NCT01166178)
- Testing
- Zoledronic Acid, Calcium and Vitamin D combination
- Where
- 15 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis
Myeloma
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
The purpose of this study test the hypothesis that the combination of simvastatin and zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose methylprednisolone and bendamustine on a day 1,8 schedule (to…
- Trial name
- NCT01332617
- Testing
- Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
- Sponsor
- University of Louisville
Prostate Cancer
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones.
- Trial name
- NCT00005073
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
Arthritis, Rheumatoid
Zoledronic Acid in Rheumatoid Arthritis
The progression of structural joint damage is the leading cause of disability and socioeconomic costs associated with rheumatoid arthritis (RA).
- Trial name
- AZAR (NCT02123264)
- Testing
- Zoledronic acid
- Where
- 11 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Carmen Gómez-Vaquero
Osteoporosis in Post-menopausal Women
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at…
- Trial name
- STRONG-HIP (NCT07772609)
- Testing
- Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU
- Where
- 9 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Sahlgrenska University Hospital